United-Guardian, Inc. provided earnings guidance for the year 2021. In a positive note, sales of their pharmaceutical products were not impacted by the pandemic, and continue to be strong. They remain optimistic that the worst of the pandemic is behind them, and that they will be able to gradually recover some of the business they lost last year. With the additional revenue that they anticipate will be generated over the next few years from some of their recently introduced products, they are hopeful that in 2021 they will begin to see a return to their previous revenue and profitability levels.